BI 655066 in patients with Crohn’s disease.

• Research type

  Research Study

• Full title

  A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist monoclonal antibody, in patients with moderately to severely active Crohn’s disease, who are naïve to, or were previously treated with anti-TNF therapy.

• IRAS ID

  138166

• Contact name

  Arthur Kaser

• Contact email

  ak729@cam.ac.uk

• Eudract number

  2013-002902-29

• ISRCTN Number

  n/a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  13/EE/0367

• Date of REC Opinion

  26 Nov 2013

• REC opinion

  Further Information Favourable Opinion